Key factors
sym | AMYT |
exch | US |
MCap | 942.76M |
Beta | 0.765 |
PE Ratio | 39.72 |
EPS | 0.37 |
Div date | 0000-00-00 |
Yesterday
sym | AMYT |
exch | US |
close | 14.7 |
50 Day MA | 14.61 |
200 Day MA | 9.990 |
52 Week High | 14.76 |
52 Week Low | 14.54 |
Target Price | 18.67 |
Market Cap Mln | 942.76 |
Share statistics
Shares Outstanding | 64.13M |
Shares Float | 37.38M |
Percent Institutions | 77.30 |
PercentInsiders | 0.078 |
SharesShort | 121.19K |
Short Ratio | 0.58 |
Shares Short Prior Month | 77633 |
Short Percent | 1.539 |
Income
Revenue TTM | 243.62M |
Revenue Per Share TTM | 3.803 |
Quarterly Revenue Growth YOY | 8.200 |
Gross Profit TTM | 120.84M |
EBITDA | -73.8M |
Diluted Eps TTM | 0.37 |
earning
Operating Margin TTM | -0.16 |
Trailing PE | 39.72 |
EPS Estimate Current Quarter | -0.05 |
EPS Estimate Next Quarter | -0.07 |
EPS Estimate Next Year | -0.03 |
Earnings Share | 0.37 |
Dividend
Dividend Date | 0000-00-00 |
Last Split Date | 0000-00-00 |
business
Enterprise Value Ebitda | 6.606 |
Enterprise Value Revenue | 2.396 |
Book Value /share | 5.069 |
Price Book MRQ | 1.400 |
Price Sales TTM | 1.874 |
ProfitMargin | -0.00 |
ReturnOnAssetsTTM | -0.03 |
ReturnOnEquityTTM | -0.00 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Pharmaceuticals |
Gic Sector | Health Care |
Gic Sub Industry | Pharmaceuticals |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Codes
ISIN | US03217L1061 |
CIK | 1783010 |
Code | AMYT |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2023-06-20 |
is Delisted | 1 |
Delisted Date | 2023-04-12 |
Home Category | ADR |
info
Fiscal Year End | December |
ForwardPE | 67.56 |
Full Time Employees | 289.0 |
IPODate | 2019-12-31 |
MostRecent Quarter | 2022-09-30 |
Contact
Name | Amryt Pharma Holdings Ltd |
Address | 45 Mespil Road, Dublin, Ireland, 4 |
Country Name | USA |
Phone | 353 1 518 0200 |
Web URL | https://www.amrytpharma.com |
Logo URL | /img/logos/US/AMYT.png |
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.